RedCloud Bio has built an innovative pipeline targeting tumor resistance, rare disease and other severe diseases with high unmet medical needs. The Company’s lead therapeutic candidate, H002, a small molecule compound addressing EGFR activating and drug-resistant mutations, is expected to enter clinical trials shortly. H002 is a promising candidate as a fourth generation TKI for NSCLC harboring EGFR activating/drug-resistant mutations.
Our Pipeline
________
Program
 Phase-III
  Phase-II    
   Phase-I   
  IND
Pre-clinical
  Target
 Indication
Click for more information
H002
RC-08       Solid Tumor          BRK
RC-X        Undisclosed        Undisclosed
NSCLC
EGFR
Contact Us

 

Taizhou   ｜Building 6, 2 Xiejiashe Road, Medical High-Tech Industrial Development Zone Beijing   ｜5th Floor, Central Laboratory Building, No. 38 Xueyuan Road Website: https://www.redcloudbio.com

Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved